Thus, the findings of the current study open the door for future mechanistic studies to investigate ADAM6 and PRSS1 in various cancer types, including both hematological malignancies and solid tumors, and shed light on the need for careful consideration of various molecular mediators interrelated with TME remodeling. Here, ADAM6 is linked to hematologic disorder.